Despite a Trump administration push, there are few facilities offering the complex treatment in the rural areas where many ...

The American Journal of Managed Care® ( AJMC®) hosted its annual event, Patient Centered-Oncology Care (PCOC), on September ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

Labroots and the Cell & Gene Therapy planning committee are thrilled to announce the 2nd Annual Cell & Gene Therapy Virtual Event Series, live on October 15, 2025. This free, interactive event brings ...

According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is projected to ...

At the Cleveland Clinic, doctors are using a one-time gene-editing therapy that alters a patient’s own blood-forming stem cells to correct the genetic mutation responsible for the disease. Physicians ...

A blood stem cell gene therapy co-developed by UCLA’s Dr. Donald Kohn restored immune function in 59 of 62 children with ADA-SCID, a rare and fatal immune disorder, with no serious complications ...

A one-time gene therapy using a patient’s own stem cells has effectively cured a deadly immune disorder in 95% of treated children, offering a lasting, donor-free solution to ADA-SCID, known as the ...

TOMI Environmental Solutions, Inc.® ('TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, ...

The search for gene therapies to treat rheumatoid arthritis (RA) has moved in fits and starts over the past two decades, with trials starting and stopping, and their focus shifting to osteoarthritis ...

Labroots is pleased to announce the 2nd annual event in the Cell & Gene Therapy Virtual Event Series, taking place on October 14th, 2026. The Cell & Gene Therapy planning committee will invite ...